Biohaven Pharmaceutical Holding Company Ltd.

07/07/2022 | Press release | Distributed by Public on 07/07/2022 05:37

Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)